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Abstract
Background: Polypharmacy, and the associated adverse drug events such as non-adherence to prescriptions, is a
common problem for elderly people living with multiple comorbidities. Deprescribing, i.e. the gradual withdrawal
from medications with supervision by a healthcare professional, is regarded as a means of reducing adverse effects
of multiple medications including non-adherence. This systematic review examines the evidence of deprescribing
as an effective strategy for improving medication adherence amongst older, community dwelling adults.
Methods: A mixed methods review was undertaken. Eight bibliographic database and two clinical trials registers
were searched between May and December 2017. Results were double screened in accordance with pre-defined
inclusion/exclusion criteria related to polypharmacy, deprescribing and adherence in older, community dwelling
populations. The Mixed Methods Appraisal Tool (MMAT) was used for quality appraisal and an a priori data collection
instrument was used. For the quantitative studies, a narrative synthesis approach was taken. The qualitative data was
analysed using framework analysis. Findings were integrated using a mixed methods technique. The review was
performed in accordance with the PRISMA reporting statement.
Results: A total of 22 original studies were included, of which 12 were RCTs. Deprescribing with adherence as an
outcome measure was identified in randomised controlled trials (RCTs), observational and cohort studies from 13
countries between 1996 and 2017. There were 17 pharmacy-led interventions; others were led by General Practitioners
(GP) and nurses. Four studies demonstrated an overall reduction in medications of which all studies corresponded with
improved adherence. A total of thirteen studies reported improved adherence of which 5 were RCTs. Adherence was
reported as a secondary outcome in all but one study.
Conclusions: There is insufficient evidence to show that deprescribing improves medication adherence. Only 13
studies (of 22) reported adherence of which only 5 were randomised controlled trials. Older people are particularly
susceptible to non-adherence due to multi-morbidity associated with polypharmacy. Bio-psycho-social factors
including health literacy and multi-disciplinary team interventions influence adherence. The authors recommend
further study into the efficacy and outcomes of medicines management interventions. A consensus on priority
outcome measurements for prescribed medications is indicated.
Trial registration: PROSPERO number CRD42017075315.
Keywords: Polypharmacy, Deprescribing, Adherence, Systematic review, Older person
* Correspondence: s.fowler-davis@shu.ac.uk
2Sheffield Hallam University, Montgomery House, 32 Collegiate Crescent,
Sheffield S10 2BP, England
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ulley et al. BMC Geriatrics           (2019) 19:15 
https://doi.org/10.1186/s12877-019-1031-4
Background
The management of many chronic diseases depends chiefly
on the assumption that the medications prescribed by the
clinician are taken by the individual being treated. Medica-
tion adherence is defined as the extent to which prescribed
medications are taken according to the dosage and fre-
quency recommended by the provider [1]. It is estimated,
however, that between 30 and 50% of people do not take
their medications as prescribed [2]. Theories as to the causes
of non-adherence generally recognise socio-economic,
healthcare system, condition- and patient-related factors [3].
Methods to combat non-adherence are wide-ranging; from
practical interventions, to behaviour change interventions
targeting psychological barriers to medication use [4]. The
resulting costs of non-adherence are both human, the indi-
vidual not gaining the benefit of treatment, and economic
[5–7], resulting in unused medication, for example. Older
people are particularly susceptible to non-adherence due to
multi-morbidity associated polypharmacy [8], and owing to
particular constraints such as physical, cognitive or sensory
impairments [9].
In this review polypharmacy is the taking of any medi-
cation that is potentially inappropriate, rather than ex-
ceeding a defined number of drugs [10] because
adherence to an inappropriate medication can lead to
harm. However, available evidence regarding polyphar-
macy and drug adherence in the older population living
at home is scarce [11]. Most studies have focused on im-
proving adherence to one drug group, and thus have
limited applicability to the older population who com-
monly use multiple medications [12–14].
The term ‘deprescribing’ is the process of the gradual
withdrawal and cessation of potentially inappropriate
medications, supervised by a healthcare professional
with the goal of reducing unnecessary medications and
their related problems [15]. Deprescribing attempts to
balance the potential for benefit and harm by systematic-
ally withdrawing inappropriate medications with the goal
of managing polypharmacy and improving outcomes
[16]. Guidelines that have been developed to facilitate
this process advocate involving the individual themselves
in decisions relating to their prescription [17–20]. In
spite of their potential to improve safety, significant bar-
riers to these interventions exist [21–23].
Previous studies have examined the impact of depre-
scribing processes in residential care settings [24]. To
the best of the authors’ knowledge, there has been no
investigation as to the potential of deprescribing as an
effective strategy for improving medication adherence
in community-dwelling older adults. This is a popula-
tion who are largely independent and live in their own
home, but for whom the number, dosage and complex-
ity of medications demands considerable health liter-
acy [25, 26].
The aim of the review was to explore the impact of
deprescribing interventions on adherence measures in
this unique population.
Methods
A mixed methods systematic review of the literature was
undertaken on deprescribing interventions and medication
adherence in community-dwelling older adults with poly-
pharmacy. Registered as PROSPERO CRD42017075315,
this systematic review used qualitative and quantitative
data to explore a range of factors associated with the effect-
iveness of deprescribing interventions in tackling medica-
tion non-adherence, and in doing so, offers a more
complete picture of the area of investigation [27]. The
search, screening, quality appraisal and data extraction pro-
cesses were led by an Information Scientist (DH) and the
lead for the review team (JU). This systematic review is re-
ported in accordance with the Preferred Reporting Items
for Systematic review and Meta-Analysis (PRISMA)
statement.
Eligibility criteria
Papers were selected using the criteria as follows. Study
type: primary qualitative, quantitative or mixed methods
studies were sought. Protocols, conference abstracts,
academic thesis, editorials, commentaries and opinion
articles were excluded. Review papers were excluded,
but were used to cross-check for relevant primary pa-
pers. Population: papers must have reported data on
community dwelling older people (aged ≥65 years) ex-
periencing polypharmacy. In this review, polypharmacy
is the taking of any medication that is potentially in-
appropriate, rather than exceeding a defined number of
drugs [10]. Intervention: a paper must have explored the
effect of a deprescribing intervention which included
any medication review that was in line with the defin-
ition agreed by the Pharmaceutical Care Network Eur-
ope 2013. [28]. Comparator: a study must have included
a control to have been eligible for inclusion. Outcomes:
a paper must have reported data on adherence, mea-
sured by any means; i.e., pill count, self-reported, ques-
tionnaire, ‘drug or prescription or medications’ ‘renewal
or refill’, blood level analysis. Adherence could have been
reported as a primary or a secondary outcome. Any
study that did not report adherence was excluded.
Search strategy
An information scientist (DH) undertook a comprehen-
sive search of eight bibliographic databases between May
and August 2017: ASSIA (ProQuest), CENTRAL (Wi-
ley), CINAHL (EBSCO), MEDLINE (EBSCO), PsycINFO
(ProQuest), Scopus (Elsevier), Sociological Abstracts
(ProQuest), Web of Science (Thomson Reuters). Two
clinical trials registers were searched in December 2017:
Ulley et al. BMC Geriatrics           (2019) 19:15 Page 2 of 13
UK Clinical Trials Gateway (NHS, National Institute for
Health Research), International Clinical Trials Registry
Platform (World Health Organization).
The search strategy comprised four facets: (i) older
people, and (ii) polypharmacy, deprescribing or medica-
tions reviews, and (iii) adherence or instruments/measure-
ments relating to adherence, and (iv) the community
setting, such as independent living, or the community
based professional delivering the intervention. All terms
were searched for in the title and abstract fields and con-
trolled vocabulary terms were included where available.
The Boolean operators AND and OR were used, alongside
truncation, phrase searching and proximity operators.
Only papers published in the English language were
sought, no date limits were applied. The search syntax
was adapted for use on each information source. The full
search strategy, written up for MEDLINE (EBSCO) is pro-
vided in Additional file 1: Appendix 1.
Data management
The bibliographic software, RefWorks (ProQuest) was
used to store and organise all results from the biblio-
graphic databases, and Excel was used for results from
the clinical trials registers. Microsoft Excel 2015 was
used to support the selection of papers and data extrac-
tion process, and Microsoft Word 2015, the quality ap-
praisal process.
Study selection
All papers retrieved from the literature searches were
assessed against the inclusion criteria. The study selec-
tion process was piloted by all members of the review
team using a sample of 100 papers. All results were in-
dependently screened by two members of the review
team. In the first instance the title and abstract of all pa-
pers were screened to determine their relevancy,
followed by a full text screening of all remaining papers.
Any disagreement in screening outcome between re-
viewers was resolved through discussion or the use of a
third reviewer. Reviewers were not blinded to a paper’s
author/s.
Data extraction
An a priori data collection instrument was created and
piloted by the review team. Data extraction was under-
taken by one reviewer and double checked for accuracy by
a second. Any discrepancies were resolved through discus-
sion and further scrutiny of the included paper. Extracted
data were as follows: information on the author/s, year of
publication, name of paper, title of journal; the study set-
ting, duration and geographic location; the study type, de-
sign, aim, objectives, context, and data collection and
analysis techniques; the number of participants, partici-
pant demographics, e.g. age, gender, baseline cognitive
function, number of medications taken, health conditions
experienced; the aim and description of the intervention,
the intervention instrument, baseline adherence, how the
intervention was delivered; time from the intervention to
the follow-up; theoretical framework underpinning an
intervention; author stated strengths/weaknesses and con-
clusions; reviewers comments. Outcomes of adherence in-
cluded: (i) the adherence measure reported, (ii) the
number of drugs prescribed and their appropriateness,
(iii) and whether the adherence measure improved with
intervention or not. Secondary measures of interest in-
cluded: self-reported quality of life, primary care visits,
hospital visits and mortality; indicators of acceptability to
users, and evidence of shared decision making.
Risk of bias in individual studies
The Mixed Methods Quality Appraisal Tool (MMAT)
[29] was used to explore the risk of bias at study level.
An overall quality score was attributed to each study. An
incremental score of 25% is given for each of the four
criteria met for quantitative and qualitative studies and
each of the three criteria for mixed methods studies.
Data synthesis
Qualitative and quantitative data were analysed separ-
ately. If a paper reported mixed methods data, a decision
was taken as to what the majority of the data comprised.
The quantitative data was not homogenous; there was
variability in data collection, data source, and statistical
analysis across most studies. Therefore for the quantita-
tive studies, a narrative synthesis approach was taken.
The qualitative data was analysed using Framework Ana-
lysis [30]. Findings were integrated using the ‘Following
a Thread’ technique described by O’Cathain et al., [31].
Using this approach all data sets were scanned for key
themes and questions in need of further exploration.
Results
A total of 1980 unique papers were yielded from the
database searches, and an additional 140 papers from
the clinical trials registers searches. Screening title and
abstracts resulted in 119 papers being retained from the
database searches and 21 papers from the clinical trials
registries. After full-text reading, author citation and ref-
erence list evaluation a total of 22 met the eligibility cri-
teria and underwent quality appraisal and data
extraction processes. Nine additional trials were found,
but no data was found due to either non-publication or
ongoing research. The literature review screening
process is summarised in Fig. 1.
Outcomes from the MMAT exercise for the 22 papers
from the database searches showed that ten studies
scored 100%, six scored 75% and six scored 50% or less.
Non-RCT data exhibited somewhat greater risk of bias
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(see MMAT summary Table 1). Quantitative and qualita-
tive findings were collated but the framework analysis
was limited by the very small amount of qualitative data
about adherence, medicines’ management methods and
patient outcomes. A summary of study characteristics
are presented in Table 2.
Studies and participants
Twenty-two studies in 13 different countries were in-
cluded (10 in Europe, 5 in North America, 7 elsewhere
(Australia, New Zealand, Taiwan, Hong Kong and
Jordan), with publication dates between 1996 and 2017,
involving 5118 participants. Thirteen studies were con-
trolled clinical trials (1 non-randomised), and nine were
cross-sectional studies. The age range of the participants
was 46 and 97 years. Three studies included patients <
65 years, 13 studies age range 65–85, 6 studies included
patients >86y. Eight study interventions were based in
primary care or GP practices, seven in community phar-
macies, three in an outpatient clinic, two as home visits,
Fig. 1 PRISMA flow diagram
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Table 2 Summary of study characteristics
Ref Study
design
Setting Study duration
(months)
Total number
of participants
(N = intervention
group where
relevant)
Type of
intervention/
person leading
Usual care
(if applicable)
Adherence outcome
Basheti
2016
Jordan
RCT Outpatient Clinic 3 112
(N = 50)
Follow up
Pharmacist
led medication
review
Routine
clinical
practice
Reduction in
self- reported
non-adherence
in intervention
group (P < 0.001)
compared with
control group
(P = 0.168)
Beer 2011
Australia
RCT Home setting
and residential
aged-care facility
Unknown 30
(N = 15)
Physician
led targeted
medication
withdrawal
Usual care No significant
difference
between the
groups
P = 0.17
Campins
2017
Spain
RCT Primary care
centres
12 503
(N = 252)
Pharmacist
led medication
review
Routine
clinical
practice
At 6 months
adherence was
higher in the
intervention
group (76.4%
v 64.1%)
P = 0.005
Grymonpre
2001
Canada
RCT Community
based clinic
Variable
(from baseline
to follow
up letter)
135
(N = 69)
Pharmacist
led medication
review
Routine
clinical
practice
No significant
impact on
adherence
from baseline
to follow-up
(P = 0.895)
Haag 2016
USA
RCT Primary care
outpatient clinic
1 25
(N = 13)
Pharmacist
led medication
review
Pre-existing
out-patient
care transition
programme
No significant
difference in
adherence
P = 0.65
Hanlon
1996
USA
RCT General Medicine
Clinic at Veterans
Affairs Medical
Centre
12 208
(N = 105)
Pharmacist
led medication
review
Usual care No significant
difference in
medication
compliance
(P = 0.88)
Hedegaard
2015
Denmark
RCT Outpatient clinics 12 532
(N = 240)
Pharmacist
led medication
review
Routine
clinical
practice
Trend toward
improved
adherence at 3, 9
and 12months.
Greater % of control
group non-adherent
compared with
intervention group
30.2% vs 20.3%
P = 0.01.
Jaeger 2017
Germany
RCT GP Practices 9 273
(N = 143)
Tailored
medication
review
programme
delivered by
GPs and Health
Care Assistants
Routine
clinical
practice
No significant
effects on
adherence
P = 0.11
Lowe 2000
UK
RCT General Practice /
Home setting
3 161
(N = 77)
Pharmacist
led review
Routine
clinical
practice
Significant difference
in mean compliance
score (tablet count
and self –reported).
Intervention
group = 91.3%
vs 79.5% control
group. P < 0.001
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Table 2 Summary of study characteristics (Continued)
Ref Study
design
Setting Study duration
(months)
Total number
of participants
(N = intervention
group where
relevant)
Type of
intervention/
person leading
Usual care
(if applicable)
Adherence outcome
Sturgess
2003
Northern
Ireland
RCT Community
Pharmacies
18 191
(N = 110)
Community
Pharmacist
intervention
programme
Routine
Practice
Significant increase
in compliance and
fewer problems with
medication compared
with control group
(P < 0.05)
Vinks 2009
Netherlands
RCT Community
Pharmacy
4 174
(N = 87)
Community
Pharmacist
review
Usual
Practice
Significant reduction
in the number of
drug related
problems per patient
(includes non-
compliance) -16.3%
(−24.3,-8.3) 95% CI
Messerli
2016
Switzerland
RCT Community
Pharmacy
7 450
(N = 218)
Community
Pharmacist
Polymedication
Check (PMC)
Routine
practice
No significant
difference in
adherence between
the two groups
could be observed
(p = 0.817)
Chen 2016
Taiwan
Prospective
cross-sectional
Outpatient
clinics
3 152 Pharmacist led
medication
therapy
management
service
Increase in
medication
adherence
(MMAS-4 scale)
from 3.02 to 3.92
(p < 0.001)
Fiss 2013
Germany
Prospective
cohort
Ambulatory
primary
healthcare
1–24
(mean = 9)
911
(N = 393)
Pharmaceutical care
from local pharmacy
plus medical
intervention by GP
Increased in
adherence
forgetfulness
P = 0.001
Increased
adherence
deliberate
p = 0.003
(n = 400)
between
baseline and
follow up
Griffiths
2004
Australia
Cohort Community /
Home setting
1 N = 24 Community nurse
medication review
Routine
clinical
practice
No significant
difference in non-
adherence pre and
post intervention
(P = 0.237)
Hatah 2014
New
Zealand
Retrospective
cohort
Community
Pharmacy
6 to 41 N = 353 Community
Pharmacist
Medicines Use
Review (MUR)
No significant
difference except
during the third
visit where more
patients with
lower adherence
scores did not
return
P < 0.001
Lee 2015
Hong Kong
Prospective
Uncontrolled
Community
outreach
8 N = 103 Pharmacist
led review
Routine clinical
practice
Significant
reduction in
Morisky
Medication
Adherence score
P = 0.005
Raynor
2000
UK
Cohort Community
Pharmacy/
home setting
2 N = 143 Community
Pharmacist led
medication
Routine
practice
Non-adherence
fell from 38%
to 14% (P < 0.001)
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one as remote prescribing and one from a community
centre for older people. The follow-up period for the in-
terventions ranged between four weeks and 41months,
with a mean of eight months.
Types of interventions
The healthcare professional leading the intervention
varied significantly. Most commonly, a pharmacist led
(in 18 studies [32–48], while a GP and pharmacist
co-led in 1 study [49], a GP alone in another study
[50], a community nurse led in another study [51]
and the participants themselves led in another [52].
While all interventions included a process of deprescrib-
ing, study interventions used ‘deprescribing’ specifically in
nine studies [32, 35, 40, 42, 47, 48, 52, 53], while in 12
studies the description was ‘medication use review’
[33, 34, 36–38, 41, 43–46, 49–51].
Where specific deprescribing tools were used they in-
cluded the GP-GP (good palliative-geriatric practice) [32],
STOPP/START, 2 [32, 39], Beers, 1 [52], e-medicines infor-
mation, one [35], IMAP (individualised medication assess-
ment and planning program), 1 [42]. In four studies no
particular deprescribing tool was mentioned [40, 47, 48, 52].
Only four of the 22 studies yielded significant reductions in
tablet burden [32, 46, 47, 50]. Regime complexity, i.e. the
frequency and dosing, was not recorded in any of the stud-
ies. Of those studies with no decrease in overall medications;
seven demonstrated a comparable number pre- and
post-intervention [33, 36, 42, 43, 45, 48, 52]; 1 study re-
ported an overall increase [44], and nine did not record the
numbers (either pre or post) [34, 35, 37–41, 49, 51, 53].
Medication adherence
Thirteen studies reported improved adherence following
study interventions [32, 34–41, 43, 46, 47, 50] of which
5 studies were RCTs. Of the four studies that report a
reduction in medication burden, all reported improved
adherence [32, 46, 47, 50]. Exclusion of studies at mod-
erate to high risk of bias (MMAT score 50% or less) did
not alter the overall findings. The adherence tool varied
between studies, but not to the same extent as the inter-
vention tool. The Morisky-Green scale or a derivative
was used in 10 studies [32–35, 38–40, 42, 46, 49, 52];
Medication possession ratio/pill count in five studies
[36, 37, 43, 45, 49, 52]; self-report only in three studies
[48, 50, 51] and self-report and pill count in three stud-
ies [44, 47, 50]. An unspecified adherence scale was used
in one study [41]. All studies reported adherence as a
secondary outcome, except Twigg [39] and Messerli
[53]. The proposed mechanisms of success for those that
reported improved adherence were: reduced number of
medications, 1 [32]; good relationship between clinical
professionals/ collaborative working, 3 [34, 43, 50]; prac-
tical aspect only, 1 [45]; educational or motivational
Table 2 Summary of study characteristics (Continued)
Ref Study
design
Setting Study duration
(months)
Total number
of participants
(N = intervention
group where
relevant)
Type of
intervention/
person leading
Usual care
(if applicable)
Adherence outcome
adherence
support
Roth 2013
USA
Prospective Community
based primary
care medical
practice
6 64 Clinical
Pharmacist led
medication
review
Routine clinical
practice
Significant
reduction in
the number of
medication
related problems
per patient
(P < 0.001)
which included
non- adherence
Steele 2016
USA
Prospective
Study
Home based 3 25 Pharmacist
conducted
home based
medication
review
Routine
practice
Non- adherence
was significantly
reduced
(P = 0.012)
Tan 2014
Australia
Prospective
Study
Community
clinic/ home
setting
6 82 Pharmacist led review Routine
practice
Significant
improvement in
adherence (44.1%
v 62.7% P = 0.023)
Twigg 2015
UK
Service
Evaluation
Community
Pharmacy
6 620 Community Pharmacist
Review
Routine
Practice
Significant
increase in
adherence 0.513
.337 to 0.689)
95% CI
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impact, 5 [36, 38–41], both practical and behavioural
impact, 3 [35, 37, 47].
In terms of the secondary measures of interest,
self-reported quality of life was reported in five of the 22
studies [32, 34, 39, 44, 48], of which one study [39] re-
ported an improvement. The other four studies had no
statistical impact. Primary care visits were reported in
four studies [32, 39, 40, 44] of which one study reported
a change in number of visits [39] (an increase from a
mean of 1.65 to 2.04 visits per patient in a 6 month
period). Unplanned or emergency care visits were re-
ported in 6 studies [32, 33, 39, 40, 42, 44]. Two studies
suggested that interventions resulted in reductions to
unplanned care but this was not statistically significant;
four studies demonstrated no impact on unplanned or
emergency care. Mortality was reported in four studies
[32, 33, 44, 45]; none of these reported any impact.
Discussion
The issue of adherence is manifestly complicated. A
broad range of studies was deliberately included to en-
hance understanding of the potential mechanisms of any
intervention effect but qualitative data were limited. It is
clear that no routine or consistent method of deprescrib-
ing is implemented, and no consistent outcome from the
practice, such as a reduction in the number of prescrip-
tions, is reported. Therefore it was impossible to demon-
strate that an improved adherence was a consequence of
a reduced medication burden.
Adherence is regarded as an important indicator of the
quality of the doctor–patient relationship [54] and by ex-
tension that offered by other multidisciplinary team mem-
bers. It is important to note that there are different
understandings of adherence according to clinical and re-
search priorities. This study identified that improved ad-
herence depended on the measurement tool and the
method of statistical analysis. For example, a self-report
scale questionnaire would differ in analysis to the propor-
tion of days covered. One study incorporated the under-
standing of the individual as to the purpose of each of
their medications [41], where others merely counted the
number of pills left at the end of a month [36, 37, 43, 47].
There is an extremely mixed body of literature report-
ing strategies to improve medication adherence [55]. Ad-
herence was measured as a secondary outcome in all but
two studies which meant that more subtle reasons for
non-adherence could not be established from this re-
view. Follow-up periods were generally short, making it
difficult to draw any conclusions as to the lasting impact
of the interventions themselves.
The range of professional practitioners engaged in
deprescribing implies that international models of prac-
tice are continuing to adopt an interdisciplinary team
approach. Of the three studies that did not involve
pharmacists, none showed a difference in adherence
measures. Of the 18 remaining studies, the majority (13
studies) demonstrated improved outcomes. From this re-
view it would seem that pharmacist-led deprescribing in-
terventions are effective.
Independent prescribing status in the UK has been
awarded by the General Pharmaceutical Council since 2006
and nurses, podiatrists, physiotherapists and therapeutic
radiographers may complete additional post-registration
training to become independent prescribers [56]. One study
commented that the success of the intervention depended,
in large part, on the physician’s acceptance of the recom-
mended changes in a person’s medications [34]. Collabora-
tive working between professionals to achieve deprescribing
or increased adherence may be key to the success of these
interventions.
A systematic method of enhancing the quality of research
into medication use is now being proposed, particularly fo-
cusing on seven factors that are consistent with the findings
of this study; vulnerable patient populations; polyphar-
macy and multi-morbidity; person-centered practice
and research; deprescribing or medicines use review;
methodological development; variability in medication
use; and national and international comparative re-
search [56].
From this review there is little data suggesting that
deprescribing interventions improve outcomes such as
quality of life, primary or secondary care visits or affect
mortality [57]. On the other hand, neither is there much
evidence that these interventions lead to a negative im-
pact on these measures; something that has already been
suggested elsewhere [58]. Large RCTs evaluating multi-
disciplinary interventions and clinical outcomes of
deprescribing are lacking [59–61], but there are exam-
ples of individual studies suggesting that deprescribing
can improve outcomes such as falls, hospital admissions
and mortality [62].
There was a surprisingly low level of reporting of
socio-economic components. In a sub group analysis of
four studies that reported both deprescribing with re-
duction in medication and an improvement in adherence
the intervention cohort (N = 847) were 44% men and
56% women. The studies reported inconsistently, on
marital status educational level and household income.
Further consideration of these socio-economic compo-
nents is indicated to deliver a patient-centred depre-
scribing process [63, 64].
The strengths of this review include careful attention
to screening and data extraction of the adherence out-
come and the focus on the outcome of the complex
medicines management intervention. ‘Deprescribing’
was carefully defined to include all forms of medication
review interventions where the intention was to reduce
treatment burden.
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The evidence found was from different study designs:
RCTs, prospective/ retrospective cohort, prospective
cross-sectional, cohort and prospective uncontrolled and
is a limitation of the literature. Meta-analyses of data
were not possible, and this is a limitation, owing to the
diversity of measures used in calculating adherence. A
number of potentially interesting sub-group analyses
(e.g. ethnicity, degree of frailty, economic impact of
intervention) could not be completed due to varied and
incomplete reporting of populations studied, interven-
tions delivered, and outcome measurements. Qualitative
data analysis revealed a number of factors associated
with non-adherence but limited narrative explanation
was possible within the data.
Conclusion
This systematic review found that deprescribing as an
intervention did not routinely improve medication ad-
herence in this patient population. The theory that a re-
duced medication burden would improve adherence
could not be substantiated in the literature. This is be-
cause the interventions described in the studies did not
convincingly reduce medication burden. There is a range
of bio-psycho-social factors reported that associate with
improved adherence, but medicines review processes
vary and rarely report the population demographic. Ad-
herence is mostly reported as a secondary outcome and
there is no standard report of successful adherence to
medication. The authors recommend further study into
the efficacy and outcomes of medicines management in-
terventions. A consensus on priority outcome measure-
ments for prescribed medications is indicated.
Additional file
Additional file 1: Appendix 1. Search terms for the study. (DOCX 17 kb)
Abbreviations
ASSIA: Applied Social Sciences Index and abstracts; CENTRAL: Cochrane
Central Register of Controlled Trails; CINAHL: Cumulative Index to Nursing
and Allied Health Literature; MEDLINE: Medical Literature; MMAT: Mixed
Methods Quality Appraisal Tool; PRISMA: Preferred Reporting Items for
Systematic review and Meta-Analysis; PROSPERO: Prospective Register of
Systematic Reviews; PsycINFO: Psychology Informatics; RCT: Randomised
Controlled Trial; USA: United States of America
Acknowledgements
The authors would like to acknowledge Andrew Adams, Clinical Pharmacist,
Northern General Hospital, Sheffield, for his contribution to the initial stages
of the review process.
Funding
This work was undertaken by arrangement between Sheffield Hallam
University and Sheffield Teaching Hospitals NHS Foundation Trust and did
not receive funding from any funding agency.
Availability of data and materials
The data and materials are available on request from the corresponding
author.
Authors’ contributions
SFD led the project, and was responsible for the review with substantial
contribution to conception, design, drafting and completion of the
manuscript. JU made substantial contribution to the conception and design,
was involved in drafting the manuscript and contributed critically for
important intellectual content. DH made substantial contributions to the
design and acquisition of data and analysis and contributed to drafting of
the manuscript, AA contributed to the design and acquisition of data and
contributed to the drafting of the manuscript. SA made a substantial
contribution to the design and acquisition of data and was involved in the
drafting of the manuscript. SFD, JU, DH, AA and SA give final approval for
the final version and take full responsibility for the content and agree to be
accountable for all aspects of the work, associated with accuracy and
integrity. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
N/A
Consent for publication
Non applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England.
2Sheffield Hallam University, Montgomery House, 32 Collegiate Crescent,
Sheffield S10 2BP, England.
Received: 11 October 2018 Accepted: 9 January 2019
References
1. Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D, et al.
Medication compliance and persistence: terminology and definitions. Value
Health. 2008;11(1):44–7.
2. World Health Organization. Adherence to Long Term Therapies. Geneva:
Evidence for Action; World Health Organization; 2003. http://www.who.int/
chp/knowledge/publications/adherence_report/en.
3. Kardas P, Lewekm P, Matyjaszczyk M. Determinants of patient adherence: a
review of systematic reviews. Front Pharmacol. 2013;4:91.
4. Patton DE, Hughes CC, Ryan M. Theory-based interventions to improve
medication adherence in older adults prescribed polypharmacy: a
systematic review. Drugs Aging. 2017;34(2):97–113.
5. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur
Heart J. 2011;32(3):264–8.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;
353(5):487–97.
7. Mickelson RS, Holden RJ. Medication adherence: staying within the
boundaries of safety. Ergonomics. 2018;61(1):82–103.
8. Pérez-Jover V, Mira JJ, Carratala-Munuera C, Gil-Guillen VF, Basora J, López-
Pineda A, et al. Inappropriate use of medication by elderly, polymedicated,
or multipathological patients with chronic diseases. Int J Enviro Res Public
Health. 2018;15(2):310.
9. Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: factors influencing
compliance with prescribed medication plans. Case Manager. 2005;16(2):47–51.
10. Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey
on polypharmacy and use of inappropriate medications. Toxicol Int. 2012;
19(1):68–73.
11. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to
medication adherence in the elderly: looking beyond cost and regime
complexity. Am J Geriatr Pharmacother. 2011;9(1):11–23.
12. Zelko E, Klemenc-Ketis Z, Tusek-Bunc K. Medication adherence in elderly
with polypharmacy living at home: a systematic review of existing studies.
Mater Sociomed. 2016;28(2):129–32.
Ulley et al. BMC Geriatrics           (2019) 19:15 Page 11 of 13
13. George J, Elliott RA, Stewart DC. A systematic review of interventions to
improve medication taking in elderly patients prescribed multiple
medications. Drugs Aging. 2008;25(4):307–24.
14. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide
of polypharmacy and drug-drug interactions: population database analysis
1995-2010. BMC Med. 2015;13(1):74.
15. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al.
Reducing inappropriate polypharmacy: the process of deprescribing. JAMA
Intern Med. 2015;175(5):827–34.
16. Page AT, Potter K, Clifford R, Etherton-Beer C. Deprescribing in older people.
Maturitas. 2016 Sep 1;91:115–34.
17. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony DO. STOPP (screening
tool of older Person’s prescriptions) and START (screening tool to alert
doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther.
2008;46(2):72–83.
18. Scottish Government Model of Care Polypharmacy Working Group.
Polypharmacy Guidance (2nd edition). 2015. Scottish Government. http://
www.sehd.scot.nhs.uk/publications/DC20150415polypharmacy.pdf.
19. National Institute for Clinical Excellence. Multimorbidity: clinical assessment
and management’ NICE Guideline [NG56]. 2016. https://www.nice.org.uk/
guidance/ng56.
20. National Institute for Clinical Excellence. Medicines optimisation: the safe and
effective use of medicines to enable the best possible outcomes’NICE guideline
(NG5) publication date March 2015. https://www.nice.org.uk/guidance/ng5.
21. Raae-Hansen C, Byrne S, O'Mahony D, Kearney PM, Sahm LJ, Cullinan S.
Challenges of deprescribing in older patients with multimorbidity, from
healthcare professionals' perspectives-a narrative review.
Pharmacoepidemiol Drug Saf. 2017;26(Suppl 1):16–7.
22. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real
need to deprescribe in older patients. Med J Aust. 2014;201(7):390–2.
23. Woodward MC. Deprescribing: achieving better health outcomes for older
people through reducing medications. Journal Pharm Pract Res. 2003;33(4):
323–8.
24. Kua CH, Yeo CYY, Char CWT, Tan CWY, Tan PC, Mak VS, et al. Nursing home
team-care deprescribing study: a stepped-wedge randomised controlled
trial protocol. BMJ Open. 2017;7(5):e015293.
25. Masnoon N, Shakib S, Kalisch L, Caughey G. Systematic review of
polypharmacy definition, assessment tools, and association with clinical
outcomes. Res Soc Admin Pharm. 2017;13(4):e28–9.
26. Mortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S.
Defining polypharmacy in the elderly: a systematic review protocol. BMJ
Open. 2016;6(3):e010989.
27. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types
and associated methodologies. Health Inf Libr J. 2009;26(2):91–108.
28. Pharmaceutical Care Network Europe ‘PCNE statement on medication
review’ v3.01012013 https://www.pcne.org/upload/files/150_20160504_
PCNE_MedRevtypes.pdf.
29. Pluye P, Robert E, Cargo M, Bartlett G, O’Cathain A, Griffiths F, et al. Proposal: A
mixed methods appraisal tool for systematic mixed studies reviews. 2011.
http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/84371689/
MMAT%202011%20criteria%20and%20tutorial%202011-06-29updated2014.08.
21.pdf. Archived by WebCite® at http://www.webcitation.org/5tTRTc9yJ.
30. Ritchie J, Spencer L. Qualitative Data Analysis for Applied Policy Research. In:
Bryman A, Burgess B, editors. Analyzing Qualitative Data. London:
Routledge: Chapter 9. Routledge, London; 1994.
31. O’Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in
mixed methods studies. BMJ. 2010;341(7783):1147.
32. Campins L, Serra-Prat M, Gózalo I, López D, Palomera E, Agustí C, et al.
Randomized controlled trial of an intervention to improve drug
appropriateness in community-dwelling polymedicated elderly people. Fam
Pract. 2017;34(1):36–42.
33. Haag JD, et al. Impact of Pharmacist-Provided medication therapy
management on healthcare quality and utilisation in recently discharged
elderly patients. Am Health Drug Benefits. 2016;9(5):259–68.
34. Basheti IA, Al-Qudah R, Obeidat NM, Bulatova NR. Home medication
management review in outpatients with chronic diseases in Jordan: a
randomized control trial. Int J Clin Pharm. 2016;38(2):404–13.
35. Chen C, Kuo L, Cheng K, Shen W, Bai K, Wang C, et al. The effect of
medication therapy management service combined with a national
PharmaCloud system for polypharmacy patients. Comput Methods Prog
Biomed. 2016;134:109–19.
36. Hedegaard U, Kjeldsen LJ, Pottegård A, Henriksen JE, Lambrechtsen J,
Hangaard J, et al. Improving Medication Adherence in Patients with
Hypertension: A Randomized Trial. Am J Med. 2015;128(12):1351–61.
37. Steele KM, Ruisinger JF, Bates J, Prohaska ES, Melton BL, Hipp S. Home-
based comprehensive medication reviews: Pharmacist's impact on drug
therapy problems in geriatric patients. Consult Pharm. 2016;31(10):598–605.
38. Lee VW, Choi LM, Wong WJ, Chung HW, Ng CK, Cheng FW. Pharmacist
intervention in the prevention of heart failure for high-risk elderly patients
in the community. BMC Cardiovasc Disord. 2015;15:178.
39. Twigg MJ, Wright D, Barton GR, Thornley T, Kerr C. The four or more
medicines (FOMM) support service: results from an evaluation of a new
community pharmacy service aimed at over-65s. Int J Pharm Pract. 2015;
23(6):407–14.
40. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist consultations in general
practice clinics: the pharmacists in practice study (PIPS). Res Social Adm
Pharm. 2014;10(4):623–32.
41. Hatah E, Tordoff J, Duffull SB, Cameron C, Braund R. Retrospective
examination of selected outcomes of medicines use review (MUR) services
in New Zealand. Int J Clin Pharm. 2014;36(3):503–12.
42. Roth MT, Ivey JL, Esserman DA, Crisp G, Kurz J, Weinberger M. Individualized
medication assessment and planning: optimizing medication use in older
adults in the primary care setting. Pharmacotherapy. 2013;33(8):787–97.
43. Vinks THAM, Egberts TCG, de Lange TM, de Koning FHP. Pharmacist-based
medication review reduces potential drug-related problems in the elderly:
the SMOG controlled trial. Drugs Aging. 2009;26(2):123–33.
44. Sturgess I, McElnay J, Hughes C, Crealey G. Community pharmacy based
provision of pharmaceutical care to older patients. Pharm World Sci. 2003;
25(5):218–26.
45. Grymonpre RE, Williamson DA, Montgomery PR. Impact of a pharmaceutical
care model for non-institutionalised elderly: results of a randomised,
controlled trial. Int J Pharm Pract. 2001;9(4):235–41.
46. Raynor DK, Nicolson M, Nunney J, Petty D, Vail A, Davies L. The
development and evaluation of an extended adherence support
programme by community pharmacists for elderly patients at home. Int J
Pharm Pract. 2000;8(3):157–64.
47. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine
review and education programme for older people in general practice. Br J
Clin Pharmacol. 2000;50(2):172–5.
48. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et
al. A randomized, controlled trial of a clinical pharmacist intervention to
improve inappropriate prescribing in elderly outpatients with polypharmacy.
Am J Med. 1996;100(4):428–37.
49. Fiβ T, Meinke-Franze C, van den Berg N, Hoffmann W. Effects of a three
party healthcare network on the incidence levels of drug related problems.
Int J Clin Pharm. 2013;35(5):763–71.
50. Jäger C, Freund T, Steinhaeuser J, Stock C, Krisam J, Kaufmann-Kolle P, et al.
Impact of a tailored program on the implementation of evidence-based
recommendations for multimorbid patients with polypharmacy in primary
care practices-results of a cluster-randomized controlled trial. Implement Sci.
2017;12(1):8.
51. Griffiths R, Johnson M, Langdon R, Piper M. A nursing intervention for the
quality use of medicines by elderly community clients. Int J Nurs Pract.
2004;10(4):166–76.
52. Beer C, Loh P, Peng YG, Potter K, Millar A. A pilot randomized controlled
trial of deprescribing. Ther Adv Drug Saf. 2011;2(2):37–43.
53. Messerli BE, Vriends N, Hersberger KE. Impact of a community pharmacist-
led medication review on medicines use in patients on polypharmacy - a
prospective randomised controlled trial. BMC Health Serv Res. 2016;16:145.
54. de Wit L, Fenenga C, Giammarchi C, di Furia L, Hutter I, de Winter A, et al.
Community-based initiatives improving critical health literacy: a systematic
review and meta-synthesis of qualitative evidence. BMC Public Health. 2018;
18:40.
55. Marcum ZA, Hanlon JT, Murray MD. Improving medication adherence and
health outcomes in older adults: an evidence-based review of randomized
controlled trials. Drugs Aging. 2017;34(3):191–201.
56. Health and Care Professions Council. Standards for prescribing. No date.
https://www.hcpc-uk.org/resources/standards/standards-for-prescribing/.
57. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility
and effect of deprescribing in older adults on mortality and health: a
systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Sep 1;82(3):
583–623.
Ulley et al. BMC Geriatrics           (2019) 19:15 Page 12 of 13
58. Tan EC, Sluggett JK, Johnell K, Onder G, Elseviers M, Morin L, et al. Research
priorities for optimizing geriatric pharmacotherapy: an international
consensus. J Am Med Dir Assoc. 2018;19(3):193–9.
59. Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of deprescribing
interventions in older hospitalised patients on prescribing and clinical
outcomes: a systematic review of randomised trials. Drugs Aging. 2018;
35(4):303–19.
60. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials:
methods to reduce polypharmacy and the impact on prescribing and
clinical outcomes. Clin Geriatr Med. 2012;28(2):237–53.
61. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility
and effect of deprescribing in older adults on mortality and health: a
systematic review and meta-analysis. Br J of Clin Pharmacol. 2016;82(3):583–
623.
62. Thomas R, Huntley AL, Mann M, Huws D, Elywn G, Paranjothy S, et al.
Pharmacist-led interventions to reduce unplanned admissions for older
people: a systematic review and meta-analysis of randomised controlled
trials. Age Ageing. 2014;43(2):174–87.
63. Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to
and enablers of deprescribing: A systematic review. Drugs Aging. 2013;30:
793–807.
64. Zermansky AG, Alldred DP, Petty DR, Raynor DK, Freemantle N, Eastaugh J,
et al. Clinical medication review by a pharmacist of elderly people living in
care homes-a randomised controlled trial. Age Ageing. 2006;35(6):586–91.
Ulley et al. BMC Geriatrics           (2019) 19:15 Page 13 of 13
